BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...European products in therapeutic categories such as cardiovascular-metabolic and anti-inflammatory products.No STAR for Tasly Bio Tasly Pharmaceutical Co. Ltd....
BioCentury | Oct 31, 2019
Financial News

I-Mab looks to fill gap in NASDAQ listings by Chinese players

...shareholders are CBC Group, with about 39% of the preprofit company’s equity; entities associated with Tasly Pharmaceutical Co. Ltd....
BioCentury | Jun 25, 2019
Financial News

June 25 Financial Quick Takes: Tasly unit planning Hong Kong IPO; plus Vesalius, Mirati and more

...China) proposed to list on the Hong Kong exchange. The company is a subsidiary of Tasly Pharmaceutical...
...clinical trial during 1Q20. Hongjiang Li and Elizabeth S. Eaton, Staff Writers ArQule Inc. Krystal Biotech Inc. Mirati Therapeutics Inc. Tasly Pharmaceutical Co. Ltd. Vesalius...
BioCentury | Oct 19, 2018
Clinical News

Pharnext planning U.S, EU submissions for Charcot-Marie-Tooth therapy on Phase III data

...to treat pediatric CMT1A patients. GeneNet Co. Ltd. (Tianjing, China), a JV between Pharnext and Tasly Pharmaceutical Co. Ltd....
...PXT3003 has Orphan Drug designation in the U.S. and EU. Pharnext S.A. (Euronext:ALPHA), Issy-Les-Moulineaux, France Tasly Pharmaceutical Co. Ltd....
BioCentury | Oct 16, 2018
Clinical News

Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data

...to treat pediatric CMT1A patients. GeneNet Co. Ltd. (Tianjing, China), a JV between Pharnext and Tasly Pharmaceutical Co. Ltd....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer PDUFA date December Pharnext S.A.S. (Euronext:ALPHA) / Tasly Pharmaceutical Co. Ltd....
BioCentury | Aug 31, 2018
Financial News

Harbin Gloria selling stake in biotech unit to new investors

...raise capital or restructure. In July, the Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) subsidiary of Tasly Pharmaceutical Co. Ltd....
BioCentury | Aug 17, 2018
Financial News

Harbin Gloria selling stake in biotech unit

...raise capital or restructure. In July, the Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) subsidiary of Tasly Pharmaceutical Co. Ltd....
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

...considering spinning out their innovative R&D units. Tasly Biopharmaceuticals is the innovative R&D unit of Tasly Pharmaceutical Co. Ltd....
...China I-Mab Biopharma, Shanghai, China Innovent Biologics Inc., Suzhou, China Stealth BioTherapeutics Corp., Newton Mass. Tasly Pharmaceutical Co. Ltd....
BioCentury | Jul 20, 2018
Financial News

Ascletis sets terms for Hong Kong IPO

...listing on HKEX. Allison Johnson Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) ravidasvir (ASC16, PPI-668) Ascletis Pharma Inc. C-Bridge Capital Tasly Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 59
BioCentury | Jan 8, 2021
Finance

Jan. 8 Quick Takes: Venture rounds for Abbisko, DiCE, Aulos, LifeMine, Mana, Theolytics and more

...European products in therapeutic categories such as cardiovascular-metabolic and anti-inflammatory products.No STAR for Tasly Bio Tasly Pharmaceutical Co. Ltd....
BioCentury | Oct 31, 2019
Financial News

I-Mab looks to fill gap in NASDAQ listings by Chinese players

...shareholders are CBC Group, with about 39% of the preprofit company’s equity; entities associated with Tasly Pharmaceutical Co. Ltd....
BioCentury | Jun 25, 2019
Financial News

June 25 Financial Quick Takes: Tasly unit planning Hong Kong IPO; plus Vesalius, Mirati and more

...China) proposed to list on the Hong Kong exchange. The company is a subsidiary of Tasly Pharmaceutical...
...clinical trial during 1Q20. Hongjiang Li and Elizabeth S. Eaton, Staff Writers ArQule Inc. Krystal Biotech Inc. Mirati Therapeutics Inc. Tasly Pharmaceutical Co. Ltd. Vesalius...
BioCentury | Oct 19, 2018
Clinical News

Pharnext planning U.S, EU submissions for Charcot-Marie-Tooth therapy on Phase III data

...to treat pediatric CMT1A patients. GeneNet Co. Ltd. (Tianjing, China), a JV between Pharnext and Tasly Pharmaceutical Co. Ltd....
...PXT3003 has Orphan Drug designation in the U.S. and EU. Pharnext S.A. (Euronext:ALPHA), Issy-Les-Moulineaux, France Tasly Pharmaceutical Co. Ltd....
BioCentury | Oct 16, 2018
Clinical News

Pharnext planning U.S., EU submissions for Charcot-Marie-Tooth therapy on Phase III data

...to treat pediatric CMT1A patients. GeneNet Co. Ltd. (Tianjing, China), a JV between Pharnext and Tasly Pharmaceutical Co. Ltd....
BioCentury | Oct 6, 2018
Finance

Seeking validation

...BRCA-mutated, HER2-negative locally advanced or metastatic breast cancer PDUFA date December Pharnext S.A.S. (Euronext:ALPHA) / Tasly Pharmaceutical Co. Ltd....
BioCentury | Aug 31, 2018
Financial News

Harbin Gloria selling stake in biotech unit to new investors

...raise capital or restructure. In July, the Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) subsidiary of Tasly Pharmaceutical Co. Ltd....
BioCentury | Aug 17, 2018
Financial News

Harbin Gloria selling stake in biotech unit

...raise capital or restructure. In July, the Tasly Biopharmaceuticals Co. Ltd. (Shanghai, China) subsidiary of Tasly Pharmaceutical Co. Ltd....
BioCentury | Aug 4, 2018
Finance

Hong Kong’s first wave

...considering spinning out their innovative R&D units. Tasly Biopharmaceuticals is the innovative R&D unit of Tasly Pharmaceutical Co. Ltd....
...China I-Mab Biopharma, Shanghai, China Innovent Biologics Inc., Suzhou, China Stealth BioTherapeutics Corp., Newton Mass. Tasly Pharmaceutical Co. Ltd....
BioCentury | Jul 20, 2018
Financial News

Ascletis sets terms for Hong Kong IPO

...listing on HKEX. Allison Johnson Ganovo, danoprevir (ASC08, ITMN-191, RG7227, r7227, ITMN B) ravidasvir (ASC16, PPI-668) Ascletis Pharma Inc. C-Bridge Capital Tasly Pharmaceutical Co. Ltd....
Items per page:
1 - 10 of 59